Price
No data yet.
Social Signal Score
Revenue
$10.27M+785.85%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Alan Campbell
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 113
- Beta
- 2.51
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 8.29
Financials
Revenue
$10.27M+785.8%Net Income
$-21.97MEBITDA
$-21.97MFree Cash Flow
$-328.0KEPS (diluted)
$-0.35Shares Outstanding (diluted)
62.94M+53.0%Operating Expenses
$41.96MCash & Debt
$970.91MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.00M | $-113.63M | $-1.83 |
| 2024 | $10.59M | $-68.99M | $-1.28 |
| 2023 | $8.08M | $-58.29M | $-1.32 |
| 2022 | $8.61M | $-63.06M | $-1.52 |
| 2021 | $3.64M | $-32.67M | $-0.79 |
| 2020 | $0.00 | $-6.78M | $-0.16 |
| 2019 | $0.00 | $-4.24M | $-0.10 |
Valuation
JANXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newszacks.com·6h ago·Positive
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
View source ↗
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.48 per share
Typical surprise +21.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.35 vs $-0.25miss
- Thu, May 7$-0.39 vs $-0.52beat
- Thu, Feb 26$-0.51 vs $-0.65beat
- Thu, Nov 6$-0.39 vs $-0.60beat
- Thu, Aug 7$-0.55 vs $-0.48miss
- Thu, May 8$-0.38 vs $-0.43beat
Estimates and results for JANX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by JANX officers and directors.
- Bought
- $25.3m
- Sold
- $1.8m
4 trades
21 trades
- Doyle Janeen Noelsold
- Dobek Mariasold
- Meyer Andrew Hollmansold
- Diraimondo Thomassold
- Campbell David Alansold
- Winter Charles M.sold
- Mciver Zachariahsold
- Dobek Mariasold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.